Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Approaches to manage 'affordability' of high budget impact medicines in key EU countries.

Flume M, Bardou M, Capri S, Sola-Morales O, Cunningham D, Levin LA, Postma MJ, Touchot N.

J Mark Access Health Policy. 2018 Jun 8;6(1):1478539. doi: 10.1080/20016689.2018.1478539. eCollection 2018. Review.

2.

Defining and Measuring the Affordability of New Medicines: A Systematic Review.

Antoñanzas F, Terkola R, Overton PM, Shalet N, Postma M.

Pharmacoeconomics. 2017 Aug;35(8):777-791. doi: 10.1007/s40273-017-0514-4. Review.

PMID:
28477220
3.

Paying for Cures: Perspectives on Solutions to the "Affordability Issue".

Schaffer SK, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A.

Value Health. 2018 Mar;21(3):276-279. doi: 10.1016/j.jval.2017.12.013. Review.

4.

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.

Schey C, Milanova T, Hutchings A.

Orphanet J Rare Dis. 2011 Sep 27;6:62. doi: 10.1186/1750-1172-6-62.

5.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
6.

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Chhatwal J, Kanwal F, Roberts MS, Dunn MA.

Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.

7.

ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA.

Hampson G, Henshall C, Towse A.

Int J Technol Assess Health Care. 2017 Jan;33(2):315-322. doi: 10.1017/S0266462317000496. Epub 2017 May 30.

PMID:
28554337
8.

Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.

Danzon PM.

Value Health. 2018 Mar;21(3):252-257. doi: 10.1016/j.jval.2017.12.018.

9.

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z.

Acta Pharm Hung. 2010;80(4):162-72. Hungarian.

PMID:
21404477
11.

Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY.

Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.

12.

[A research roadmap for complementary and alternative medicine - what we need to know by 2020].

Fischer F, Lewith G, Witt CM, Linde K, von Ammon K, Cardini F, Falkenberg T, Fønnebø V, Johannessen H, Reiter B, Uehleke B, Weidenhammer W, Brinkhaus B.

Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24.

13.

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Danzon PM, Drummond MF, Towse A, Pauly MV.

Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.

14.

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.

Pearson SD.

Value Health. 2018 Mar;21(3):258-265. doi: 10.1016/j.jval.2017.12.017. Review.

15.
16.

Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.

Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2017 Jul 31;5(1):1355203. doi: 10.1080/20016689.2017.1355203. eCollection 2017.

17.

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.

Jørgensen J, Servos S, Kefalas P.

J Mark Access Health Policy. 2018 Aug 6;6(1):1500419. doi: 10.1080/20016689.2018.1500419. eCollection 2018.

18.

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B.

Front Pharmacol. 2016 Jul 22;7:197. doi: 10.3389/fphar.2016.00197. eCollection 2016.

19.

Health Technology Assessment, International Reference Pricing, and Budget Control Tools from China's Perspective: What Are the Current Developments and Future Considerations?

Koh L, Glaetzer C, Chuen Li S, Zhang M.

Value Health Reg Issues. 2016 May;9:15-21. doi: 10.1016/j.vhri.2015.06.004. Epub 2015 Oct 1.

PMID:
27881254

Supplemental Content

Support Center